The 2022 Panjiayuan Consensus Conference, held by the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, has introduced pivotal advancements in prostate targeted biopsy (TB) strategies and development, marking a significant leap forward in the diagnosis and management of prostate cancer (PCa).
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.